Antitumor effect of lung cancer vaccine with umbilical blood dendritic cells in reconstituted SCID mice
/in International Publications, NSCLC /von 2008-06-01 / Cancer Biother. Radiopharm. 2008 Jun;23(3):321-31IFN-gamma down-regulates Hsp27 and enhances hyperthermia-induced tumor cell death in vitro and tumor suppression in vivo
/in International Publications, NSCLC /von 2008-06-01 / Int. J. Oncol. 2008 Jun;32(6):1317-24Radiotherapy with 8-MHz radiofrequency-capacitive regional hyperthermia for stage III non-small-cell lung cancer: the radiofrequency-output power correlates with the intraesophageal temperature and clinical outcomes
/in International Publications, NSCLC /von 2008-05-29 / Int. J. Radiat. Oncol. Biol. Phys. 2009 Jan;73(1):128-35Hyperthermia switches glucose depletion-induced necrosis to apoptosis in A549 lung adenocarcinoma cells
/in International Publications, NSCLC /von 2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):851-60Delivery of whole tumor lysate into dendritic cells for cancer vaccination
/in Dendritic Cells, Hypernephroma, International Publications, NSCLC /von 2008-01-01 / Methods Mol. Biol. 2008;423:139-53[Study on the cell apoptosis induced by intracellular hyperthermia in human lung adenocarcinoma SPC-A1 cells]
/in International Publications, NSCLC /von 2007-12-01 / Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2007 Dec;24(6):1305-8Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study
/in International Publications, NSCLC /von 2007-10-06 / BMC Cancer 2007 Oct;7:189Regional hyperthermia combined with radiotherapy for locally advanced non-small cell lung cancers: a multi-institutional prospective randomized trial of the International Atomic Energy Agency
/in International Publications, NSCLC /von 2007-06-27 / Int. J. Clin. Oncol. 2007 Jun;12(3):192-8Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells
/in Dendritic Cells, International Publications, NSCLC /von 2007-05-16 / Lung Cancer 2007 Sep;57(3):365-72IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de